[Ip-health] 2017 Methodology Report for the 2018 Access to Medicine Index – now online
dedwards at accesstomedicinefoundation.org
Thu Oct 5 08:27:47 PDT 2017
Dear Ip-health colleagues,
Today, we published the methodology for the 2018 Access to Medicine Index.
It can be downloaded here:
It presents the latest good practice framework for pharmaceutical companies
working to improve access to medicine. Developed over the last year through
internal analysis, stakeholder engagement and consultations through our
committees, the methodology will track where and how pharmaceutical
companies are taking action, including in strategy, compliance, R&D,
pricing, patenting, donations and capacity building.
This latest methodology has a tighter focus on where pharmaceutical
companies have the greatest potential to make change. In 2017, the Index
research team applied stricter standards when assessing whether to
strengthen, merge or remove each metric. New indicators were developed in
response to changing global health priorities, including one that captures
how companies are responding to R&D priorities set by WHO and others, and
other new metrics that will evaluate the quality of access initiatives and
how impact is being assessed.
The 2018 Access to Medicine Index will rank the same 20 pharmaceutical
companies as in the 2016 Access to Medicine Index. Considering their size,
resources, pipelines, portfolios and global reach, these companies have a
critical role to play in improving access to medicine. Together, they
account for more than 50% of the global pharmaceutical market: AbbVie Inc.,
Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim Gmbh,
Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli
Lilly & Co., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson,
Merck & Co. Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc.,
Roche Holding AG, Sanofi, Takeda Pharmaceutical Co. Ltd.
In 2017, the Foundation debated core issues with people from WHO, NGOs,
academics, governments, Product Development Partnerships, patient
organisations, industry associations, pharmaceutical companies, investors
and business analysts. This includes more than 40 named experts working to
improve access to medicine for poor populations. Strategic guidance was
provided by the Expert Review Committee (ERC), a panel of independent
experts from the WHO, governments, patient organisations, the industry,
NGOs, academia, and investors, among others.
* Targeted analysis of priority R&D. WHO and others have called for 45
diseases to be urgently prioritised for further R&D, including 12 pathogens
that pose a critical risk of antimicrobial resistance. The 2018 Index will
assess how pharmaceutical companies are responding to these calls.
* Cancer is now in scope. Cancer incidence continues to rise in low- and
middle-income countries. In 2018, the Index will assess companies’ actions
in relation to cancer for the first time.
* New metrics for capturing the quality and impact of access initiatives.
In 2018, the Index will take a deeper look at the quality of companies’
capacity building initiatives, comparing a selection against a framework of
good practice standards developed by the Index research team. The Index
will also deepen its analysis of where and how companies monitor and
measure the impact of their access-to-medicine activities.
The Foundation will begin collecting data for the 2018 Access to Medicine
Index in January next year. Following a process of data submission,
clarification and verification, the Index team will identify trends and
best practices, benchmarking the access-to-medicine profiles of each
company against its peers. The results will be published in the 2018 Access
to Medicine Index report, late next year.
My team and I are happy to discuss any aspect of the new methodology.
More information about the Ip-health